| Literature DB >> 29393702 |
Dimitrios Psimadas1, Varvara Valotassiou1, Sotiria Alexiou1, Ioannis Tsougos1, Panagiotis Georgoulias1.
Abstract
Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).Entities:
Keywords: Antibodies; PSMA; prostate cancer; radiolabeling
Mesh:
Substances:
Year: 2018 PMID: 29393702 DOI: 10.1080/07357907.2018.1430816
Source DB: PubMed Journal: Cancer Invest ISSN: 0735-7907 Impact factor: 2.176